{
  "first_published_at": "2013-03-25", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON254816", 
  "title": "Botulinum toxin type B (Neurobloc): serious known risks such as toxin spread reported mostly with off-label use ", 
  "tags": "{\"parsed_therapeutic\": [\"neurology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Neurology\"]}", 
  "_document_number": 79, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "neurology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Botulinum toxin type B (Neurobloc): serious known risks such as toxin spread reported mostly with off-label use </h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: March 2013</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Botulinum toxin type B (Neurobloc) is indicated only for the treatment of cervical dystonia (torticollis) in adults. We recommend that prescribers adhere to the licensed indication as its safety outside these circumstances has not been established. Cases of the known rare risk of toxin spread have been reported with all botulinum toxin products. Importantly, the cases with botulinum toxin type B were mostly reported with its off-label use.<br>\nAll patients receiving any product containing botulinum toxin should be warned of the signs and symptoms of toxin spread, such as muscle weakness and breathing difficulties, and advised to seek medical attention immediately if they experience breathing difficulties, choking, or any new or worsening swallowing difficulties, as such side effects may be life-threatening.<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Botulinum toxin type B (Neurobloc) is indicated only for the treatment of cervical dystonia (torticollis) in adults. The safety of botulinum toxin type B has not been established outside this licensed indication. We recommend that prescribers adhere to the licensed indication.</p>\n\n<h3>Possible risks associated with off-label use</h3>\n\n<p>Rare cases of distant toxin spread from the site of injection have been reported with botulinum toxin type B (and botulinum toxins as a class) &#8211; see article in <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON079276\">October 2007 Drug Safety Update</a>.</p>\n\n<p>Some of the cases with botulinum toxin type B occurred in patients with underlying neuromuscular deficits, in children, and other off-label use. Medically severe adverse reactions related to the spread of toxin, such as dysphagia and breathing difficulties have usually occurred in association with incorrect clinical use or off label use, such as the use in children or patients with significant neuromuscular disease, or the use of higher than recommended doses.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Reported cases of toxin spread with botulinum toxin type B have mostly occurred with off-label use; we therefore recommend that prescribers adhere to the licensed indication</li>\n</ul>\n\n<ul>\n<li>Botulinum toxin type B should not be used in children, or in patients with known neuromuscular disease or neuromuscular junction disorders.</li>\n\n<li>The risk of toxin spread with botulinum toxins is rare but serious and has been reported with all products in this class. All patients receiving a medicine containing botulinum toxin should be warned of the signs and symptoms of toxin spread, such as muscle weakness and breathing difficulties, and advised to seek medical attention immediately if they experience breathing difficulties, choking, or any new or worsening swallowing difficulties, as such side effects can be life-threatening.</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a href=\" http://www.medicines.org.uk/EMC/searchresults.aspx?term=Neurobloc&#38;searchtype=QuickSearch\" target=\"_blank\">Updated product information for Neurobloc</a></p>\n\n<p><a href=\"/home/groups/comms-ic/documents/websiteresources/con241829.pdf\" target=\"_blank\">Letter to healthcare professionals on Neurobloc sent in February 2013</a></p>\n\n<p><a href=\"http://www.medicinescomplete.com/mc/bnf/current/PHP3174-botulinum-toxin-type-b.htm\" target=\"_blank\">BNF section 4.9.3 Drugs used in essential tremor, chorea, tics, and related disorders</a></p>\n\n<p><em>Article citation: Drug Safety Update March 2013, vol 6, issue 8: A3</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Botulinum toxin type B (Neurobloc) is indicated only for the treatment of cervical dystonia (torticollis) in adults. The safety of botulinum toxin type B has not been established outside this licensed indication. We recommend that prescribers adhere to the licensed indication.</p>\n\n<h3>Possible risks associated with off-label use</h3>\n\n<p>Rare cases of distant toxin spread from the site of injection have been reported with botulinum toxin type B (and botulinum toxins as a class) &#8211; see article in <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON079276\">October 2007 Drug Safety Update</a>.</p>\n\n<p>Some of the cases with botulinum toxin type B occurred in patients with underlying neuromuscular deficits, in children, and other off-label use. Medically severe adverse reactions related to the spread of toxin, such as dysphagia and breathing difficulties have usually occurred in association with incorrect clinical use or off label use, such as the use in children or patients with significant neuromuscular disease, or the use of higher than recommended doses.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Reported cases of toxin spread with botulinum toxin type B have mostly occurred with off-label use; we therefore recommend that prescribers adhere to the licensed indication</li>\n</ul>\n\n<ul>\n<li>Botulinum toxin type B should not be used in children, or in patients with known neuromuscular disease or neuromuscular junction disorders.</li>\n\n<li>The risk of toxin spread with botulinum toxins is rare but serious and has been reported with all products in this class. All patients receiving a medicine containing botulinum toxin should be warned of the signs and symptoms of toxin spread, such as muscle weakness and breathing difficulties, and advised to seek medical attention immediately if they experience breathing difficulties, choking, or any new or worsening swallowing difficulties, as such side effects can be life-threatening.</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a href=\"http://www.medicines.org.uk/EMC/searchresults.aspx?term=Neurobloc&amp;searchtype=QuickSearch\" target=\"_blank\">Updated product information for Neurobloc</a></p>\n\n<p><a href=\"http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con241829.pdf\" target=\"_blank\">Letter to healthcare professionals on Neurobloc sent in February 2013</a></p>\n\n<p><a href=\"http://www.medicinescomplete.com/mc/bnf/current/PHP3174-botulinum-toxin-type-b.htm\" target=\"_blank\">BNF section 4.9.3 Drugs used in essential tremor, chorea, tics, and related disorders</a></p>\n\n<p><em>Article citation: Drug Safety Update March 2013, vol 6, issue 8: A3</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2013-03-01", 
  "date_last_modified": "2013-04-09", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "Letter to healthcare professionals on Neurobloc sent in February 2013", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con241829.pdf", 
      "filename": "downloads/2da5f8fe96b9fd46a5fed96f28c1fcff073a3517/con241829.pdf", 
      "original_filename": "con241829.pdf"
    }
  ], 
  "_item_id": 79, 
  "summary": "Botulinum toxin type B (Neurobloc) is indicated only for the treatment of cervical dystonia (torticollis) in adults. We recommend that prescribers adhere to the licensed indication as its safety outside these circumstances has not been established. Cases of the known rare risk of toxin spread have been reported with all botulinum toxin products. Importantly, the cases with botulinum toxin type B were mostly reported with its off-label use.\nAll patients receiving any product containing botulinum toxin should be warned of the signs and symptoms of toxin spread, such as muscle weakness and breathing difficulties, and advised to seek medical attention immediately if they experience breathing difficulties, choking, or any new or worsening swallowing difficulties, as such side effects may be life-threatening.", 
  "body": "Article date: March 2013\n\nBotulinum toxin type B (Neurobloc) is indicated only for the treatment of cervical dystonia (torticollis) in adults. The safety of botulinum toxin type B has not been established outside this licensed indication. We recommend that prescribers adhere to the licensed indication.\n\n### Possible risks associated with off-label use\n\nRare cases of distant toxin spread from the site of injection have been reported with botulinum toxin type B (and botulinum toxins as a class) – see article in [October 2007 Drug Safety Update](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON079276).\n\nSome of the cases with botulinum toxin type B occurred in patients with underlying neuromuscular deficits, in children, and other off-label use. Medically severe adverse reactions related to the spread of toxin, such as dysphagia and breathing difficulties have usually occurred in association with incorrect clinical use or off label use, such as the use in children or patients with significant neuromuscular disease, or the use of higher than recommended doses.\n\nAdvice for healthcare professionals:  \n  \n  * Reported cases of toxin spread with botulinum toxin type B have mostly occurred with off-label use; we therefore recommend that prescribers adhere to the licensed indication  \n  * Botulinum toxin type B should not be used in children, or in patients with known neuromuscular disease or neuromuscular junction disorders.  \n  * The risk of toxin spread with botulinum toxins is rare but serious and has been reported with all products in this class. All patients receiving a medicine containing botulinum toxin should be warned of the signs and symptoms of toxin spread, such as muscle weakness and breathing difficulties, and advised to seek medical attention immediately if they experience breathing difficulties, choking, or any new or worsening swallowing difficulties, as such side effects can be life-threatening.  \n  \nFurther information:\n\n[Updated product information for Neurobloc](http://www.medicines.org.uk/EMC/searchresults.aspx?term=Neurobloc&searchtype=QuickSearch)\n\n[ASSET_TAG](#ASSET0)\n\n[BNF section 4.9.3 Drugs used in essential tremor, chorea, tics, and related disorders](http://www.medicinescomplete.com/mc/bnf/current/PHP3174-botulinum-toxin-type-b.htm)\n\nArticle citation: Drug Safety Update March 2013, vol 6, issue 8: A3\n"
}